Recovery of striatal dopamine function after acute amphetamine- and methamphetamine-induced neurotoxicity in the vervet monkey

Brain Research

Volumn 766, Issue 1-2, 1997, Pages 113-120

  Melega, William P ^a   Raleigh, Michael J ^a,b   Stout, David B ^a   Lacan, Goran ^a   Huang, Sung Cheng ^a   Phelps, Michael E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Amphetamine; Dopamine; Methamphetamine; Neurotoxicity; PET; Primate

Indexed keywords

AMPHETAMINE; DOPAMINE; METHAMPHETAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; MALE; MONKEY; NERVE CELL PLASTICITY; NEUROTOXICITY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC NERVE; PRIORITY JOURNAL; REGULATORY MECHANISM; STEADY STATE; STRIATE CORTEX; SUBSTANTIA NIGRA;

ACUTE DISEASE; AMPHETAMINE; ANIMALS; CERCOPITHECUS AETHIOPS; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HOMOVANILLIC ACID; MALE; METHAMPHETAMINE; NEUROTOXINS; SUBSTANTIA NIGRA; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030984414     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(97)00548-9     Document Type: Article

References (41)

1. Barrio J.R., Huang S.C., Melega W.P., Yu D.C., Hoffman J.M., Schneider J.S., Satyamurthy N., Mazziotta J.C., Phelps M.E. 6-[18F]fluoro-L-dopa probes dopamine turnover rates in central dopaminergic structures. J. Neurosci. Res. 27:1990;487-493.
2. J.F. Bowyer, R.R. Holson, Methamphetamine and amphetamine neurotoxicity, in: L.W. Chang, R.S. Dyers (Eds.), Handbook of Neurotoxicology, Marcel Dekker, New York, 1995, pp. 845-870.
3. Brooks D.J., Ibanez V., Sawle G.V., Quinn N., Lees A.J., Mathias C.J., Banniister R., Marsden C.D., Frackowiak R.S.J. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Ann. Neurol. 28:1990;547-555.
4. Brunswick D.J., Benmansour S., Tejani-butt S.M., Hauptmann M. Effects of high-dose methamphetamine on monoamine uptake sites in rat brain measured by quantative autoradiography. Synapse. 11:1992;287-293.
5. 18F-dopa PET data, J. Neurol. Neurosurg. Psychiatry 57 (1994) 278-284.
6. Commissiong J.W. Monoamine metabolites: their relationship and lack of relationship to monoaminergic neuronal activity. Biochem. Pharmacol. 34:1985;1127-1131.
7. Cutler P.D., Cherry S.R., Hoffman E.J., Digby W.M., Phelps M.E. Design features and performance of a PET system for animal research. J. Nucl. Med. 33:1992;595-604.
8. Elsworth J.D., Deutch A.Y., Redmond J.D.E., Sladek J.J.R., Roth R.H. MPTP-induced parkinsonism: relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area, and retrorubral field of symptomatic and asymptomatic vervet monkeys. Brain Res. 513:1990;320-324.
9. Fibiger H., McGeer E. Effect of acute and chronic methamphetamine treatment on tyrosine hydroxylase activity in brain and adrenal medulla. Eur. J. Pharmacol. 16:1971;176-180.
10. Huang S.C., Yu D.C., Barrio J.R., Grafton S., Melega W.P., Hoffman J.M., Satyamurthy N., Mazziotta J.C., Phelps M.E. Kinetics and modeling of L-6-[18F]fluoro-dopa in human positron emission tomographic studies. J. Cereb. Blood Flow Metab. 11:1991;898-913.
11. Kitt C.A., Cork L.C., Eidelberg F., Joh T.H., Price D.L. Injury of nigral neurons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a tyrosine hydroxylase immunocytochemical study in monkey. Neuroscience. 17:1986;1089-1103.
12. Kordower J.H., Freeman T.B., Snow B.J., Vingerhoets F.J., Mufson E.J., Sandberg P.R., Hauser R.A., Smith D.A., Nauert G.M., Perl D.P. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. New Engl. J. Med. 332:1995;1118-1124.
13. Kuczenski R., Segal D. Concomitant characterization of behavioral and striatal neurotransmitter response to amphetamine using in vivo microdialysis. J. Neurosci. 9:1989;2051-2065.
14. Luxen A., Monclus M., Hendrickx P., Masson C. Synthesis and HPLC separation of 6-Fluoro-L-DOPA metabolites. Bull. Soc. Chim. Belg. 103:1993;217-225.
15. W. Martin, A. Stoessl, M. Adam, J. Grierson, T. Ruth, B. Pate, D. Calne, Imaging of dopamine systems in human subjects exposed to MPTP, in: MPTP: a neurotoxin producing a parkinsonian syndrome, Academic Press, 1986, pp. 315-325.
16. Melega W.P., Raleigh M., Stout D., DeSalles A., Blurton-Jones M., Cherry S., Huang S.-C., Blurton-Jones M., Morton G., Huang S.-C., Phelps M. Longitudinal behavioral and 6-[18F]Fluoro-L-DOPA-PET assessment in MPTP-hemiparkinsonian monkeys. Exp. Neurol. 141:1996;318-329.
17. Melega W.P., Raleigh M.J., Stout D., Huang S.-C., ME. P. Ethological and 6-[18F]Fluoro-L-DOPA-PET profiles of long term vulnerability to chronic amphetamine. Behav. Brain Res. 84:1997;259-268.
18. Melega W.P., Grafton S.T., Huang S.C., Satyamurthy N., Phelps M.E., Barrio J.R. L-6-[18F]fluoro-dopa metabolism in monkeys and humans: biochemical parameters for the formulation of tracer kinetic models with positron emission tomography. J. Cereb. Blood Flow Metab. 11:1991;890-897.
19. Melega W.P., Hoffman J.M., Schneider J.S., Phelps M.E., Barrio J.R. 6-[18F]fluoro-L-dopa metabolism in MPTP-treated monkeys: assessment of tracer methodologies for positron emission tomography. Brain Res. 543:1991;271-276.
20. Melega W.P., Luxen A., Perlmutter M.M., Nissenson C.H., Phelps M.E., Barrio J.R. Comparative in vivo metabolism of 6-[18F]fluoro-L-dopa and [3H]L-dopa in rats. Biochem. Pharmacol. 39:1990;1853-1860.
21. 18F]Fluoro-L-DOPA-PET studies show partial reversibility of long-term effects of chronic amphetamine in monkeys. Synapse. 22:1996;63-69.
22. Pate B.D., Kawamata T., Yamada T., McGeer E.G., Hewitt K.A., Snow B.J., Ruth T.J., Calne D.B. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann. Neurol. 34:1993;331-338.
23. Patlak C.S., Blasberg R.G. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J. Cereb. Blood Flow Metab. 5:1985;584-590.
24. Patlak C.S., Blasberg R.G., Fenstermacher J.D. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J. Cerebral Blood Flow Metab. 3:1983;1-7.
25. Ricaurte G.A., Guillery R.W., Seiden L.S., Schuster C.R., Moore R.Y. Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res. 235:1982;93-103.
26. Ricaurte G.A., Seiden L.S., Schuster C.R. Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibers. Brain Res. 303:1984;359-364.
27. Robinson T.E., Becker J.B. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res. Rev. 11:1986;157-198.
28. Robinson T.E., Camp D.M. Long-lasting effects of escalating doses d-amphetamine on brain monoamines, amphetamine-induced stereotyped behavior and spontaneous nocturnal locomotion. Pharmacol. Biochem. Behav. 26:1987;821-827.
29. Sawle G.V., Leenders K.L., Brooks D.J., Harwood G., Lees A.J., Frackowiak R.S.J., Marsden C.D. Dopa-responsive dystonia: [18F]dopa positron emission tomography. Ann. Neurol. 30:1991;24-30.
30. L. Seiden, Neurotoxicity of methamphetamine: mechanisms of action and issues related to aging. NIDA Res. Monograph. Methamphetamine Abuse: Epidemiological Issues and Implication, 1991, pp. 24-32.
31. Seiden L.S., Fischman M.W., Schuster C.R. Changes in brain catecholamines induced by long-term methamphetamine administration in rhesus monkeys. Drug Alcohol Depend. 1:1976;215-219.
32. Snow B.J., Tooyama I., McGeer E.G., Yamada T., Calne D.B., Takahashi H., Kimura H. Human positron emission tomographic [18F]Fluorodopa studies correlate with dopamine cell counts and levels. Ann. Neurol. 34:1993;324-330.
33. Steranka L.R., Sanders-Bush E. Long-term effects of continuous exposure to amphetamine in brain dopamine concentration and synaptosomal uptake in mice. Eur. J. Pharmacol. 65:1980;439-443.
34. Takikawa S., Dhawan V., Chaly T., Robeson W., Dahl R., Zanzi I., Mandel F., Spetsieris P., Eidelberg D. Input functions for 6-[Fluorine-18] fluorodopa quantitation in Parkinsonism: comparative studies and clinical correlations. J. Nucl. Med. 35:1994;955-963.
35. Turjanski N., Bhatia K., Burn D.J., V S.G., Marsden C.D., Brooks D.J. Comparison of striatal 18F-dopa uptake in adult-onset parkinsonism, parkinson's disease, and dopa-responsive dystonia. Neurology. 43:1993;1563-1568.
36. Vingerhoets F.J., Snow B.J., Tetrud J.W., Langston J.W., Schulzer M., Calne D.B. Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann. Neurol. 36:1994;765-770.
37. Volkow N.D., Fowler J.S., Gatley S.J., Logan J., Wang G., Ding Y., Dewey S. PET evaluation of the dopamine system of the human brain. J. Nucl. Med. 37:1996;1242-1256.
38. Wilson J.M., Kalasinsky K.S., Levey A.I., Bergeron C., Reiber G., Anthony R.M., Schmunk G.A., Shannak K., Haycock J.W., Kish S.J. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nature Med. 2:1996;699-703.
39. Woolverton W.L., Ricaurte G.A., Forno L.S., Seiden L.S. Long-term effects of chronic methamphetamine administration in rhesus monkeys. Brain Res. 486:1989;73-78.
40. Yu D.C., Huang S.C., Barrio J.R., Phelps M.E. The assessment of the non-equilibrium effect in the 'Patlak analysis' of Fdopa PET studies. Phys. Med. Biol. 40:1995;1243-1254.
41. Yu D.C., Huang S.C., Grafton S.T., Melega W.P., Barrio J.R., Mazziotta J.C., Phelps M.E. Methods for improving quantitation of putamen uptake constant of FDOPA in PET studies. J. Nucl. Med. 34:1993;679-688.